enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Enfortumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Enfortumab_vedotin

   Enfortumab vedotin is indicated for the treatment of adults with locally advanced (when cancer has grown too large to be surgically removed) or metastatic (when cancer cells spread to other parts of the body) urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.

3. Monomethyl auristatin E - Wikipedia

   en.wikipedia.org/wiki/Monomethyl_auristatin_E

   Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.

4. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

   www.aol.com/news/seattle-genetics-enfortumab...

   The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

5. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

   www.aol.com/news/seagens-sgen-maa-enfortumab...

   The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

6. Tisotumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Tisotumab_vedotin

   Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor , and monomethyl auristatin E (MMAE), a potent inhibitor of cell division .

7. Depatuxizumab mafodotin - Wikipedia

   en.wikipedia.org/wiki/Depatuxizumab_mafodotin

   148 251.25 g·mol −1 Depatuxizumab mafodotin ( INN ; development code ABT-414 ) is an antibody-drug conjugate designed for the treatment of cancer. [ 1 ] [ 2 ] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.

8. Encorafenib - Wikipedia

   en.wikipedia.org/wiki/Encorafenib

   Encorafenib is indicated in combination with binimetinib, for the treatment of people with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test; [2] in combination with cetuximab, for the treatment of adults with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy; [2] in ...

9. Enavatuzumab - Wikipedia

   en.wikipedia.org/wiki/Enavatuzumab

   This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.